FDA issues final guidance on abuse‐deterrent opioids

Publisher： John Wiley & Sons Inc

E-ISSN： 1556-7591|27|15|6-6

ISSN： 1042-1394

Source： ALCOHOLISM AND DRUG ABUSE WEEKLY, Vol.27, Iss.15, 2015-04, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

FDA issues final guidance on abuse‐deterrent opioids

By  

THE BROWN UNIVERSITY CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY UPDATE, Vol. 17, Iss. 5, 2015-05 ,pp. : 8-8

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of abuse‐deterrent OxyContin on prescription opioid utilization

By  

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 24, Iss. 2, 2015-02 ,pp. : 197-204

John Wiley & Sons Inc

Access to resources Recommend Favorite

New SAMHSA head issues clear guidance on NREPP, opioids: Evidence and MAT

By  

ALCOHOLISM AND DRUG ABUSE WEEKLY, Vol. 30, Iss. 4, 2018-01 ,pp. : 1-3

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended‐Release Oxycodone Formulations with Abuse‐Deterrent Properties

By  

PAIN MEDICINE, Vol. 16, Iss. 11, 2015-11 ,pp. : 2142-2151

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ticagrelor FDA Approval Issues Revisited

By  

Cardiology, Vol. 122, Iss. 3, 2012-07 ,pp. : 144-147

Karger

Access to resources Recommend Favorite